Primary biliary cholangitis

36,994views

Primary biliary cholangitis

Gastroenterology and Metabolism

Gastroenterology and Metabolism

Abdominal pain: Clinical
Gastroesophageal reflux disease (GERD)
Gastroesophageal reflux disease (GERD): Clinical
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Esophagitis: Clinical
Esophageal disorders: Clinical
Esophageal surgical conditions: Clinical
Esophageal cancer
Acid reducing medications
Esophageal disorders: Pathology review
Gastrointestinal bleeding: Clinical
Gastrointestinal bleeding: Pathology review
Pediatric gastrointestinal bleeding: Clinical
Peptic ulcers and stomach cancer: Clinical
Zollinger-Ellison syndrome
Pancreatic neuroendocrine neoplasms
Helicobacter pylori
Peptic ulcer
Gastric cancer
Gastric motility
Malabsorption syndromes: Pathology review
Malabsorption: Clinical
Short bowel syndrome (NORD)
Celiac disease
Celiac disease: Nursing process (ADPIE)
Lactose intolerance
Small bowel ischemia and infarction
Superior mesenteric artery syndrome
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Diverticulosis and diverticulitis
Laxatives and cathartics
Diverticular disease: Pathology review
Elimination disorders: Clinical
Volvulus
Irritable bowel syndrome
Bowel obstruction
Antidiarrheals
Ulcerative colitis
Crohn disease
Colorectal polyps
Colorectal polyps and cancer: Pathology review
Juvenile polyposis syndrome
Familial adenomatous polyposis
Peutz-Jeghers syndrome
Colorectal cancer: Clinical
Colorectal cancer
Anal conditions: Clinical
Acute pancreatitis
Pancreatitis: Pathology review
Pancreatitis: Clinical
Chronic pancreatitis
Pancreatic cancer
Viral hepatitis
Viral hepatitis: Clinical
Hepatitis medications
Hepatitis A and Hepatitis E virus
Hepatitis B and Hepatitis D virus
Hepatitis C virus
Viral hepatitis: Pathology review
Autoimmune hepatitis
Primary biliary cholangitis
Primary sclerosing cholangitis
Jaundice: Pathology review
Alcohol-associated liver disease
Cirrhosis: Pathology review
Cirrhosis
Cirrhosis: Clinical
Portal hypertension
Wilson disease
Hemochromatosis
Hepatocellular carcinoma
Benign liver tumors
Non-alcoholic fatty liver disease
Liver anatomy and physiology
Acute cholecystitis
Chronic cholecystitis
Gallbladder disorders: Pathology review
Gallbladder disorders: Clinical
Biliary colic
Gallbladder carcinoma
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Acute intermittent porphyria
Vitamin D
Osteomalacia and rickets
Major depressive disorder with seasonal pattern
Hypercalcemia
Hypocalcemia
Parathyroid conditions and calcium imbalance: Clinical
Bone disorders: Pathology review
Osteoporosis
Iron deficiency anemia
Metabolic acidosis
Respiratory acidosis
Renal tubular acidosis: Pathology review
Metabolic and respiratory acidosis: Clinical
Acid-base disturbances: Pathology review
Metabolic alkalosis
Respiratory alkalosis
Metabolic and respiratory alkalosis: Clinical
Hypernatremia
Hypernatremia: Clinical
Hyponatremia
Hyponatremia: Clinical
Hyperkalemia
Hyperkalemia: Clinical
Hypokalemia: Clinical
Hypokalemia
Electrolyte disturbances: Pathology review
Phosphate, calcium and magnesium homeostasis
Hypomagnesemia
Diabetes mellitus
Diabetes mellitus: Clinical
Diabetes mellitus: Pathology review
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Dyslipidemias: Pathology review
Gout
Gout and pseudogout: Pathology review
Bacteroides fragilis

Transcript

Watch video only

Content Reviewers

Primary biliary cholangitis and cirrhosis, or PBC, is an autoimmune disease where the T cells attack the cells that line the smaller-sized bile ducts in the liver.

As the cells are damaged or destroyed by immune attack, they start letting bile leak through their tight junctions and into the interstitial space, where it can get into the blood and the other liver cells.

This can cause inflammation and symptoms that are similar to cholestasis and obstructive jaundice, both of which there’s some disturbance in bile flow.

At first it presents as chronic inflammation, which is where it gets the name cholang-itis, for inflammation of the bile ducts, but advanced stages of the disease leads to cirrhosis as more cells are destroyed both from the autoimmune attack and infiltration of bile.

As with a lot of autoimmune diseases, the exact reason why T-cells start attacking these bile duct cells is unknown, and it’s likely related to genetic predisposition in combination with environmental triggers, and is associated with other autoimmune diseases like autoimmune hepatitis and Sjogren’s syndrome.

PBC tends to affect women at a much higher rate than men, about a 9:1 female to male ratio.

For some reason that has yet to be completely figured out, in almost all cases of PBC, your body creates antibodies to mitochondria, specifically a mitochondrial protein called PDC-E2; for that reason, one of the most notable markers in PBC are these antibodies to mitochondrial proteins (or AMAs) in the patient’s blood, as many as 95% of patients with PBC have AMAs in their blood.

Why though, are the bile duct cells specifically targeted? Don’t all cells have mitochondria? Shouldn’t these AMA’s be targeting all cells then?

One theory is based on a concept called molecular mimicry, where the antigens that bring about this autoimmune response are really similar to another protein, but different enough so that the immune system gets confused and thinks it’s a foreign version of that particular protein.

Here’s an example of two people’s cells, they both have this triangle protein, but they have different colored triangles, each person’s immune knows that these are their own proteins, their own self-proteins and that they shouldn’t attack, but they have antibodies for proteins that are very similar, but definitely different from self, so say they have antibodies for triangles, just different colored triangles, so like person A has red, yellow, and blue, just not green, and person B has green, yellow, and blue, and not red. So both these people’s immune systems are like yep, these are all self so we’re good.

But now say person B’s red triangle turns into a green triangle instead, the immune system’s like...huh, weird, that’s not red, that must not be ours, and so the green triangle antibody binds it and the immune system kicks in, destroys the cell, and starts making a ton of these matched antibodies.

So similarly with PBC, you’ve got these AMAs for foreign versions of the PDC-E2 protein in your mitochondria, so like maybe yours is a red triangle, so you don’t have antibodies to red triangle PDC-E2 because your immune system knows that red equals self.

So the theory is, and mind you this is most definitely a theory, on why patients with PBC have a ton of these AMAs in their blood for PDC-E2 is that some infection or maybe a chemical in the bile ducts, an environmental trigger of some kind, damages a bile duct cell in such a way that now it shows a protein that happens to be really similar to PDC-E2 in structure, so it’s a triangle, but it’s different enough to be non-self, so maybe it’s green in color instead of red; and this triggers an immune response to this particular green-triangle protein, which is similar but not the same as the red-triangle protein in the mitochondria, and so the immune system starts pumping out these green-triangle anti- mitochondrial antibodies or AMAs, even though the target antigen isn’t even necessarily from the mitochondria, it’s just sort of mimicking the structure of the mitochondrial protein! Wild eh? That’s the theory, anyway, and sort of helps explain why just the bile duct cells are being attacked, and not all cells.

Key Takeaways

Primary biliary cirrhosis (PBC), also referred to as primary biliary cholangitis, is a chronic autoimmune disease that affects the liver. It is characterized by the progressive destruction of the small bile ducts in the liver, which leads to inflammation, fibrosis, and ultimately cirrhosis (scarring) of the liver. Symptoms may not appear until the later stages of the disease but can include fatigue, itching, jaundice, and abdominal pain. Treatment involves drugs like ursodeoxycholic acid (UDCA) and cholestyramine, which slow the progression of the disease and improve symptoms. In advanced cases, liver transplantation may be necessary.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Primary biliary cirrhosis" The Lancet (2011)
  6. "Primary biliary cirrhosis" Hepatology (2009)
  7. "Primary biliary cirrhosis and autoimmune cholangiopathy" Clinics in Liver Disease (2004)